Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 1/2008

01.01.2008 | Hepatic and Pancreatic Tumors

Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?

verfasst von: Stefaan Mulier, Yicheng Ni, Jacques Jamart, Luc Michel, Guy Marchal, Theo Ruers

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Surgical resection is the gold standard in the treatment of resectable colorectal liver metastases (CRLM). In several centers, resection is being replaced by radiofrequency ablation (RFA), even though there is no evidence yet from randomized trials to support this. The aim of this study was to critically review the oncological evidence for and against the use of RFA for resectable CRLM.

Methods

An exhaustive review of RFA of colorectal metastases was carried out.

Results

Five-year survival data after RFA for resectable CRLM are not available. Percutaneous RFA is associated with worse local control, worse staging, and a small risk of electrode track seeding when compared with resection (level V evidence). For tumors ≤3 cm, local control after surgical RFA is equivalent to resection, especially if applied by experienced physicians to nonperivascular tumors (level V evidence). There is indirect evidence for profoundly different biological effects of RFA and resection.

Conclusions

A subgroup of patients has been identified for whom local control after RFA might be equivalent to resection. Whether this is true, and whether this translates into equivalent survival, remains to be proven. The time has come for a randomized trial.
Literatur
1.
Wilson SM, Adson MA. Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg 1976; 111:330–4PubMed
2.
Wanebo HJ, Semoglou C, Attiyeh F, Stearns MJ Jr. Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg 1978; 135:81–5PubMedCrossRef
3.
Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984; 199:502–8PubMedCrossRef
4.
Scheele J, Stangl R, Altendorf Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77:1241–6PubMedCrossRef
5.
Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235:759–66PubMedCrossRef
6.
Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation,and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239:818–25PubMedCrossRef
7.
Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438–47PubMedCrossRef
8.
Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88:980–5PubMedCrossRef
9.
Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 2003; 46(10 Suppl):S22–31PubMed
10.
Yasui K, Shimizu Y, Hirai T, Kanemitsu Y, Kato T. Surgical treatment for colorectal liver metastases—results of multi-institute study for effects of radical hepatectomy. Gan To Kagaku Ryoho 2004; 31:690–4PubMed
11.
Mutsaerts EL, van Ruth S, Zoetmulder FA, Rutgers EJ, Hart AA, van Coevorden F. Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. J Gastrointest Surg 2005; 9:178–86PubMedCrossRef
12.
Seifert JK, Springer A, Baier P, Junginger T. Liver resection or cryotherapy for colorectal liver metastases: a prospective case control study. Int J Colorectal Dis 2005; 20:507–20PubMedCrossRef
13.
Aldrighetti L, Castoldi R, Di Palo S, et al. Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases. Chir Ital 2005; 57:555–70PubMed
14.
Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241:715–22PubMedCrossRef
15.
Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006; 13:668–76PubMedCrossRef
16.
Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006; 141:460–6PubMedCrossRef
17.
Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94:982–99PubMedCrossRef
18.
Liang AM, Mo QG, Yang NW, Zhao YN, Yuan WP. Comprehensive therapy for primary liver cancer: a report of 607 cases. Ai Zheng 2004; 23:211–4PubMed
19.
Vogl TJ, Straub R, Eichler K, Sollner O, Mack MG. Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy-local tumor control rate and survival data. Radiology 2004; 230:450–8PubMedCrossRef
20.
Lencioni RA. Tumor Radiofrequency Ablation Italian Network (TRAIN): long-term results in hepatic colorectal cancer metastases. Paper presented at: Radiological Society of North America, 90th Scientific Assembly and Annual Meeting; November 28–December 3, 2004; Chicago, IL
21.
Pereira PL, Clasen S, Hoffmann RT, Jakobs TF, Herberts T, Helmberger TK. Long-term survival after CT- and MR-guided percutaneous radiofrequency ablation of colorectal metastases: clinical results of the German Study Group. Paper presented at: Radiological Society of North America, 92nd Scientific Assembly and Annual Meeting; November 26–December 1, 2006; Chicago, IL
22.
Gillams AR, Lees WR. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 2004; 14:2261–7PubMedCrossRef
23.
Solbiati L, Ierace T, Brioschi M, Cova L. Radiofrequency ablation of liver metastases of colorectal origin with intention to treat: local response rate and long-term survival over 7-year follow-up. Paper presented at: Radiological Society of North America, 92nd Scientific Assembly and Annual Meeting; November 26–December 1, 2006; Chicago, IL
24.
Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006; 12:318–26PubMedCrossRef
25.
Yu NC, Kim YJ, Raman SS, Lu DS, Boyadzhyan L, Hsu M. Intraoperative radiofrequency ablation of unresectable liver metastases from colorectal carcinoma: long-term results in 50 patients. Paper presented at: Radiological Society of North America, 92nd Scientific Assembly and Annual Meeting; November 26–December 1, 2006; Chicago, IL
26.
Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007; 33:67–71PubMedCrossRef
27.
Tanabe KK, Curley SA, Dodd GD, Siperstein AE, Goldberg SN. Radiofrequency ablation: the experts weigh in. Cancer 2004; 100:641–50PubMedCrossRef
28.
Solbiati L, Livraghi T, Ierace T, Meloni F, Cova L, Goldberg SN. Radiofrequency ablation for liver colorectal metastases: is it possible to equal the 5-year survival rates of surgery? Paper presented at: Radiological Society of North America, 90th Scientific Assembly and Annual Meeting; November 28–December 3, 2004; Chicago, IL
29.
Livraghi T, Meloni F. Removal of liver tumours using radiofrequency waves. Ann Chir Gynaecol 2001; 90:239–45PubMed
30.
Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach.” Cancer 2003; 97:3027–35PubMedCrossRef
31.
Livraghi T, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time” approach—reply. Cancer 2003; 98:2304–5CrossRef
32.
Gillams AR, Lees WR. Radiofrequency ablation of colorectal liver metastases. Abdom Imaging 2005; 30:419–26PubMedCrossRef
33.
Schindera ST, Nelson RC, Delong DM, Clary B. Intrahepatic tumor recurrence after partial hepatectomy: value of percutaneous radiofrequency ablation. J Vasc Interv Radiol 2006; 17:1631–7PubMedCrossRef
34.
Elias D, De Baere T, Smayra T, Ouellet JF, Roche A, Lasser P. Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg 2002; 89:752–6PubMedCrossRef
35.
Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235:863–71PubMedCrossRef
36.
Donckier V, Van Laethem JL, Ickx B, Van Gansbeke D, Goldman S, Gelin M. Local ablative treatments for liver metastases: the current situation. Acta Chir Belg 2003; 103:452–7PubMed
37.
Evrard S, Becouarn Y, Fonck M, Brunet R, Mathoulin-Pelissier S, Picot V. Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination. Eur J Surg Oncol 2004; 30:399–406PubMedCrossRef
38.
Evrard S, Mathoulin-Pelissier S. Controversies between surgical and percutaneous radiofrequency ablation. Eur J Surg Oncol 2006; 32:3–5PubMedCrossRef
39.
Pessaux P, Lermite E, Brehant O, Tuech JJ, Lorimier G, Arnaud JP. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006; 93:1–7PubMedCrossRef
40.
Joosten J, Ruers T. Local radiofrequency ablation techniques for liver metastases of colorectal cancer. Crit Rev Oncol Hematol 2007; 62:153–163PubMedCrossRef
41.
Bremers AJ, Ruers TJ. Prudent application of radiofrequency ablation in resectable colorectal liver metastasis. Eur J Surg Oncol 2007; 33:752–756PubMed
42.
Elias D, Baton O, Sideris L, Matsuhisa T, Pocard M, Lasser P. Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol 2004; 11:500–5PubMedCrossRef
43.
Elias D, Baton O, Sideris L, et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 2005; 90:36–42PubMedCrossRef
44.
Wagman LD. More tools, new strategies: enlarging the therapeutic scope for the patient with liver metastases from colorectal cancer. J Surg Oncol 2007; 95:1–3PubMedCrossRef
45.
Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003; 90:1240–3PubMedCrossRef
46.
Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243:321–8PubMedCrossRef
47.
Lu MD, Kuang M, Liang LJ, et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006; 86:801–5PubMed
48.
Sørensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 2007; 48:253–8PubMedCrossRef
49.
Birth M, Hildebrand P, Dahmen G, Ziegler A, Broring DC, Hillert C, Bruch HP. Present state of radio frequency ablation of liver tumors in Germany. Chirurg 2004; 75:417–23PubMedCrossRef
50.
Mahid SS, Hornung CA, Minor KS, Turina M, Galandiuk S. Systematic reviews and meta-analysis for the surgeon scientist. Br J Surg 2006; 93:1315–24PubMedCrossRef
51.
Bolton JS. Recurrence and outcomes following hepatic resection, radiofrequency ablation,and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239:826
52.
van Duijnhoven FH, Jansen MC, Junggeburt JM, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol 2006; 13:651–8PubMedCrossRef
53.
Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7:593–600PubMed
54.
Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies. Results in 123 patients. Ann Surg 1999; 230:1–8PubMedCrossRef
55.
Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005; 242:158–71PubMedCrossRef
56.
Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST, Wong J. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg 2004; 239:441–9PubMedCrossRef
57.
Hubert C, Gras J, Goffette P, et al. Percutaneous and surgical radiofrequency ablation for liver malignancies: a different philosophy of treatment? Acta Chir Belg 2005; 105 suppl:54
58.
Hildebrand P, Leibecke T, Kleemann M, Mirow L, Birth M, Bruch HP, Burk C. Influence of operator experience in radiofrequency ablation of malignant liver tumours on treatment outcome. Eur J Surg Oncol 2006; 32:430–4PubMedCrossRef
59.
Amersi FF, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, Bilchik AJ. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. Arch Surg 2006; 141:581–7PubMedCrossRef
60.
de Meijer VE, Verhoef C, Kuiper JW, Alwayn IP, Kazemier G, Ijzermans JN. Radiofrequency ablation in patients with primary and secondary hepatic malignancies. J Gastrointest Surg 2006; 10:960–73PubMedCrossRef
61.
Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R, Sayre J. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003; 14:1267–74PubMed
62.
Ahmad A, Chen SL, Kavanagh MA, Allegra DP, Bilchik AJ. Radiofrequency ablation of hepatic metastases from colorectal cancer: are newer generation probes better? Am Surg 2006; 72:875–9PubMed
63.
Kokudo N, Miki Y, Sugai S, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002; 137:833–40PubMedCrossRef
64.
Feliberti EC, Nelson RA, Holt A, Roybal J, Rouse L, Wagman LD. Radiofrequency ablation of small hepatic malignancies provides local control equal to resection. Paper presented at: 2007 American Hepato-Pancreato-Biliary Association Congress; April 19–22, 2007; Las Vegas, NV
65.
Elias D, Sideris L, Pocard M, de Baere T, Dromain C, Lassau N, Lasser P. Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation). Ann Surg Oncol 2005; 12:298–302PubMedCrossRef
66.
Shen P, Fleming S, Westcott C, Challa V. Laparoscopic radiofrequency ablation of the liver in proximity to major vasculature: effect of the Pringle maneuver. J Surg Oncol 2003; 83:36–41PubMedCrossRef
67.
Jaeck D. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol 2003; 10:1007–11PubMedCrossRef
68.
Elias DM, Ouellet JF. Incidence, distribution, and significance of hilar lymph node metastases in hepatic colorectal metastases. Surg Oncol Clin N Am 2003; 12:221–9PubMedCrossRef
69.
Nakamura S, Suzuki S. Treatment strategy for hepatic metastases of colorectal cancer. Nippon Geka Gakkai Zasshi 2003; 104:701–6PubMed
70.
Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 2002; 38:1023–33PubMedCrossRef
71.
Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol 2006; 32:632–6PubMedCrossRef
72.
Mazziotti A, Grazi GL, Gardini A, Cescon M, Pierangeli F, Ercolani G, Jovine E. An appraisal of percutaneous treatment of liver metastases. Liver Transpl Surg 1998; 4:271–5PubMedCrossRef
73.
Solbiati L, Ierace T, Livraghi T, Meloni F, Goldberg SN, Gazelle GS. Outcome and long-term survival of patients with liver metastases from colorectal cancer treated with percutaneous cool-tip radiofrequency ablation. Radiology 2001; 221(Suppl):P625–6
74.
Bonatti H, Bodner G, Obrist P, Bechter O, Wetscher G, Oefner D. Skin implant metastasis after percutaneous radio-frequency therapy of liver metastasis of a colorectal carcinoma. Am Surg 2003; 69:763–5PubMed
75.
Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226:441–51PubMedCrossRef
76.
Danza FM, Crucitti A, Pirulli G, Cirillo M, Magistrelli P, Bock E, Bonomo L. Complications after radiofrequency thermal ablation (RFA) of abdominal tumors: a retrospective review. Eur Radiol 2005; 15(Suppl 1):275
77.
Jaskolka JD, Asch MR, Kachura JR, et al. Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol 2005; 16:485–91PubMed
78.
Curley SA, Marra P, Beaty K, et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004; 239:450–8PubMedCrossRef
79.
Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg 2002; 89:1206–22PubMedCrossRef
80.
Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for HCC before liver transplantation? No, please don’t. J Hepatol 2005; 43:563–8PubMedCrossRef
81.
Jansen MC, Snoeren NS, Rijken AM, et al. Vitality of tumour tissue at the needle after local liver ablation. Ned Tijdschr Heelk 2006; 15:114
82.
Sofocleous CT, Nascimento RG, Klimstra D, Gonen M, Petrovic L, Brown KT. Histopathology of tissue on the probe after RFA of liver malignancies can predict local progression: initial results. JVIR 2007; 18(Suppl 1 Pt 2):S8
83.
Miao Y, Ni Y, Mulier S, et al. Ex vivo experiment on radiofrequency liver ablation with saline infusion through a screw tip cannulated electrode. J Surg Res 1997; 71:19–24PubMedCrossRef
84.
Gillams AR, Lees WR. CT mapping of the distribution of saline during radiofrequency ablation with perfusion electrodes. Cardiovasc Intervent Radiol 2005; 28:476–80PubMedCrossRef
85.
Ni Y, Mulier S, Miao Y, Michel L, Marchal G. A review of the general aspects of radiofrequency ablation. Abdom Imaging 2005; 30:381–400PubMedCrossRef
86.
Llovet J M, Vilana R, Bru C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33:1124–9PubMedCrossRef
87.
Jones OM, Rees M, John TG, Bygrave S, Plant G. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg 2005; 92:1165–8PubMedCrossRef
88.
Vigano L, Ferrero A, Sgotto E, Polastri R, Muratore A, Capussotti L. Parenchyma sparing: evolution of the resective surgical approach of hepatic metastasis from the colorectum. Suppl Tumori 2005; 4:S35PubMed
89.
Solbiati L, Ierace T, Goldberg SN, Dellanoce M, Cova L, Gazelle GS. Radiofrequency thermal ablation of liver metastases. In: Bartolozzi C, Lencioni R, eds. Liver Malignancies. Diagnostic and Interventional Radiology. New York: Springer, 1999:339–53
90.
Seki T, Tamai T, Ikeda K, et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol 2001; 13:291–4PubMedCrossRef
91.
Takada Y, Kurata M, Ohkohchi N. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol 2003; 8:332–5PubMedCrossRef
92.
Nicoli N, Casaril A, Hilal MA, et al. A case of rapid intrahepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation. Am J Surg 2004; 188:165–7PubMedCrossRef
93.
Ruzzenente A, Manzoni GD, Molfetta M, et al. Rapid progression of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol 2004; 10:1137–40PubMed
94.
Kotoh K, Enjoji M, Arimura E, Morizono S, Kohjima M, Sakai H, Nakamuta M. Scattered and rapid intrahepatic recurrences after radio frequency ablation for hepatocellular carcinoma. World J Gastroenterol 2005; 11:6828–32PubMed
95.
Angonese C, Baldan A, Cillo U, et al. Complications of radiofrequency thermal ablation in hepatocellular carcinoma: what about “explosive” spread? Gut 2006; 55:435–6PubMedCrossRef
96.
Baldan A, Marino D, De Giorgio M, et al. Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. Aliment Pharmacol Ther 2006; 24:1495–501PubMedCrossRef
97.
Kotoh K, Nakamuta M, Morizono S, et al. A multi-step, incremental expansion method for radio frequency ablation: optimization of the procedure to prevent increases in intra-tumor pressure and to reduce the ablation time. Liver Int 2005; 25:542–7PubMedCrossRef
98.
Topal B, Aerts JL, Roskams T, Fieuws S, Van Pelt J, Vandekerckhove P, Penninckx F. Cancer cell dissemination during curative surgery for colorectal liver metastases. Eur J Surg Oncol 2005; 31:506–11PubMedCrossRef
99.
Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237:860–9PubMedCrossRef
100.
Haemmerich D, Schutt DJ, Will JA, Striegel RM, Webster JG, Mahvi DM. A device for radiofrequency assisted hepatic resection. Conf Proc IEEE Eng Med Biol Soc 2004; 4:2503–6PubMed
101.
Haghighi KS, Wang F, King J, Daniel S, Morris DL. In-line radiofrequency ablation to minimize blood loss in hepatic parenchymal transection. Am J Surg 2005; 190:43–7PubMedCrossRef
102.
Ayav A, Bachellier P, Habib NA, Pellicci R, Tierris J, Milicevic M, Jiao LR. Impact of radiofrequency assisted hepatectomy for reduction of transfusion requirements. Am J Surg 2007; 193:143–8PubMedCrossRef
103.
Lupo L, Gallerani A, Panzera P, Tandoi F, Di Palma G, Memeo V. Randomized clinical trial of radiofrequency-assisted versus clamp-crushing liver resection. Br J Surg 2007; 94:287–91PubMedCrossRef
104.
Rossi P, De Majo A, Mauti A, et al. Bloodless hepatic resection with automatic bipolar radiofrequency generator and multielectrode device. Minim Invasive Ther Allied Technol 2007; 16:66–72PubMedCrossRef
105.
Zacharoulis D, Tzovaras G, Rountas C, Poultsidis A, Katsogridakis E, Sioka E, Hatzitheofilou C. Modified radiofrequency-assisted liver resection: a new device. J Surg Oncol 2007; 96:254–257PubMedCrossRef
106.
Möller PH, Ivarsson K, Stenram U, Radnell M, Tranberg KG. Comparison between interstitial laser thermotherapy and excision of an adenocarcinoma transplanted into rat liver. Br J Cancer 1998; 77:1884–92PubMed
107.
Mizutani J, Hiraoka T, Yamashita R, Miyauchi Y. Promotion of hepatic metastases by liver resection in the rat. Br J Cancer 1992; 65:794–7PubMed
108.
Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg 1995; 19:226–34PubMedCrossRef
109.
de Jong KP, Brouwers MA, van Veen ML, et al. Serum obtained from rats after partial hepatectomy enhances growth of cultured colon carcinoma cells. Invasion Metastasis 1998–1999; 18:155–64CrossRef
110.
von Breitenbuch P, Kohl G, Guba M, Geissler E, Jauch KW, Steinbauer M. Thermoablation of colorectal liver metastases promotes proliferation of residual intrahepatic neoplastic cells. Surgery 2005; 138:882–7CrossRef
111.
Harun N, Nikfarjam M, Muralidharan V, Christophi C. Liver regeneration stimulates tumour metastases. J Surg Res 2007; 138:284–90PubMedCrossRef
112.
Meredith K, Haemmerich D, Qi C, Mahvi D. Hepatic resection but not radiofrequency ablation results in tumor growth and increased growth factor expression. Ann Surg 2007; 245:771–6PubMedCrossRef
113.
Masson S, Daveau M, Hiron M, Lyoumi S, Lebreton JP, Teniere P, Scotte M. Differential regenerative response and expression of growth factors following hepatectomy of variable extent in rats. Liver 1999; 19:312–7PubMedCrossRef
114.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18:1135–49PubMed
115.
Zeng ZS, Guillem JG. Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancer. Br J Cancer 1998; 78:349–51PubMed
116.
Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003; 90:1556–64PubMedCrossRef
117.
Li BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK. Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. World J Gastroenterol 2005; 11:3046–50PubMed
118.
Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 2004; 23:119–35PubMedCrossRef
119.
Frich L, Bjornland K, Pettersen S, Clausen OP, Gladhaug IP. Increased activity of matrix metalloproteinase 2 and 9 after hepatic radiofrequency ablation. J Surg Res 2006; 135:297–304PubMedCrossRef
120.
Oka M, Hazama S, Suzuki M, et al. Depression of cytotoxicity of nonparenchymal cells in the liver after surgery. Surgery 1994; 116:877–82PubMed
121.
Karpoff HM, Tung C, Ng B, Fong Y. Interferon gamma protects against hepatic tumor growth in rats by increasing Kupffer cell tumoricidal activity. Hepatology 1996; 24:374–9PubMedCrossRef
122.
Hänsler J, Neureiter D, Strobel D, et al. Cellular and vascular reactions in the liver to radio-frequency thermo-ablation with wet needle applicators. Study on juvenile domestic pigs. Eur Surg Res 2002; 34:357–63PubMedCrossRef
123.
Wissniowski TT, Hänsler J, Neureiter D, et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 2003; 63:6496–500PubMed
124.
den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64:4024–9CrossRef
125.
Zhang JP, Pan HM, Fang Y, Huang LP, Wu JM. Impact of radiofrequency on splenocyte immunity of mice bearing H22 liver cancer. Ai Zheng 2006; 25:34–9PubMed
126.
Dromi SA, Herby S, Walsh M, Sudheendra D, Fry T, Wood B. RFA induces a tumor-specific immune response: a new role for RFA in immunotherapy. JVIR 2007; 18(Suppl 1 Pt 2):S66
127.
Haen S, Gouttefangeas C, Boss A, et al. Radiofrequency ablation may activate the immune system and induce specific anti-tumoral immune responses in cancer patients. Eur Radiol 2005; 15(Suppl 1):475
128.
Hänsler J, Wissniowski TT, Schuppan D, Witte A, Bernatik T, Hahn EG, Strobel D. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 2006; 12:3716–21PubMed
129.
Zerbini A, Pilli M, Penna A, Pelosi G, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006; 66:1139–46PubMedCrossRef
130.
den Brok MH, Sutmuller RP, Nierkens S, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res 2006; 66:7285–92CrossRef
131.
den Brok MH, Sutmuller RP, Nierkens S, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006; 95:896–905CrossRef
132.
Schueller G, Stift A, Friedl J, et al. Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells. Int J Oncol 2003; 22:1397–402PubMed
133.
Ivarsson K, Myllymaki L, Jansner K, Bruun A, Stenram U, Tranberg KG. Heat shock protein 70 (HSP 70) after laser thermotherapy of an adenocarcinoma transplanted into rat liver. Anticancer Res 2003; 23:3703–12PubMed
134.
Schueller G, Kettenbach J, Schueller-Weidekamm C, Lammer J. Heat shock protein expression by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo. Paper presented at: Radiological Society of North America, 92nd Scientific Assembly and Annual Meeting; November 26–December 1, 2006; Chicago, IL
135.
Schueller G, Kettenbach J, Sedivy R, Stift A, Friedl J, Gnant M, Lammer J. Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo. Int J Oncol 2004; 24:609–13PubMed
136.
137.
Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002; 2:185–94PubMedCrossRef
138.
Mosser DD, Caron AW, Bourget L, Denis-Larose C, Massie B. Role of the human heat shock protein hsp 70 in protection against stress-induced apoptosis. Mol Cell Biol 1997; 17:5317–27PubMed
139.
Sliutz G, Karlseder J, Tempfer C, Orel L, Holzer G, Simon MM. Drug resistance against gemcitabine and topotecan mediated by constitutive hsp 70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br J Cancer 1996; 74:172–7PubMed
140.
Roigas J, Wallen ES, Loening SA, Moseley PL. Effects of combined treatment of chemotherapeutics and hyperthermia on survival and the regulation of heat shock proteins in Dunning R3327 prostate carcinoma cells. Prostate 1998; 34:195–202PubMedCrossRef
141.
Abe T, Gotoh S, Higashi K. Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells. Biochim Biophys Acta 1999; 1445:123–3PubMed
142.
Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock protein hsp 70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993; 85:570–4PubMedCrossRef
143.
144.
Mulier S, Ni Y, Miao Y, Rosiere A, Khoury A, Marchal G. Size and geometry of hepatic radiofrequency lesions. Eur J Surg Oncol 2003; 29:867–78PubMedCrossRef
145.
Figueras J, Llado L. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection. The “test-of-time” approach. Cancer 2003; 98:2303–4PubMedCrossRef
146.
Pedersen IK, Burcharth F, Roikjær O, Baden H. Resection of liver metastases from colorectal cancer. Indications and results. Dis Colon Rectum 1994; 37:1078–82PubMedCrossRef
147.
Simon CJ, Cheah YL, Iannitti DA, Safran HP, Dupuy DE. Radiofrequency ablation of colorectal liver metastases: a 6-year retrospective study. J Vasc Interv Radiol 2006; 17 supplement 2 part 2, S32
148.
149.
Benoist S, Nordlinger B. Radiofrequency ablation in liver tumours. Ann Oncol 2004; 15(Suppl 4):iv313–7PubMed
150.
Mulier S, Ni Y, Frich L, et al. Experimental and clinical radiofrequency ablation: proposal for standardized description of coagulation size and geometry. Ann Surg Oncol 2007; 14:1381–96PubMedCrossRef
151.
Ruers TJ, de Jong KP, Ijzermans JN. Radiofrequency for the treatment of liver tumours. Dig Surg 2005; 22:245–53PubMedCrossRef
152.
McKay A, Dixon E, Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg 2006; 93:1192–201PubMedCrossRef
153.
Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007; 25:978–86PubMedCrossRef
154.
Rasmussen F. Radiofrequency ablation of liver metastases improves the survival rate of patients with metastatic colorectal disease. Acta Radiol 2007; 48:250–1PubMedCrossRef
155.
Primrose JN. Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut 2002; 50:1–5PubMedCrossRef
Metadaten
Titel
Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?
verfasst von
Stefaan Mulier
Yicheng Ni
Jacques Jamart
Luc Michel
Guy Marchal
Theo Ruers
Publikationsdatum
01.01.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9478-5

Weitere Artikel der Ausgabe 1/2008

Annals of Surgical Oncology 1/2008 Zur Ausgabe

Breast Oncology

Desmoid Tumors (Fibromatoses) of the Breast: A 25-Year Experience

Multimedia

Pancreaticoduodenectomy for Cancer: Technical Aspects of the Retroperitoneal Soft Tissue Dissection to Maximize a Negative Surgical Margin

Breast Oncology

The Critical Role of Axillary Ultrasound and Aspiration Biopsy in the Management of Breast Cancer Patients with Clinically Negative Axilla

Melanomas

N-Ratio: a Novel Independent Prognostic Factor for Patients with Stage-III Cutaneous Melanoma

Endocrine Tumors

Author Reply

Letter to the Editor

Does Lymphadenectomy Improve Survival of Patients with Solid Tumors?

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.